Quarterly ResultMay 7, 2026, 04:13 PM
Maravai LifeSciences Q1 Revenue +41%; Raises FY26 Guidance
AI Summary
Maravai LifeSciences reported strong first-quarter 2026 financial results, with total revenue increasing by 40.5% year-over-year to $65.8 million. The company returned to positive free cash flow, generating $4.2 million in the quarter, and significantly improved its Adjusted EBITDA to $20.3 million from a loss in the prior year. Following this performance, Maravai LifeSciences raised its full-year 2026 revenue guidance to $205.0 million - $215.0 million and Adjusted EBITDA guidance to $30.0 million - $32.0 million.
Key Highlights
- Q1 2026 total revenue was $65.8 million, an increase of 40.5% year-over-year.
- Q1 2026 net loss was $(6.4) million, significantly improved from $(52.9) million in Q1 2025.
- Q1 2026 Adjusted EBITDA was $20.3 million, up from $(10.5) million in Q1 2025.
- Q1 2026 free cash flow was $4.2 million, marking a return to positive cash flow.
- TriLink revenue increased 65.1% year-over-year to $47.5 million, including $14.3 million from COVID CleanCap.
- Cygnus revenue grew 1.4% year-over-year to $18.4 million.
- Full-year 2026 revenue guidance raised to $205.0 million - $215.0 million.
- Full-year 2026 Adjusted EBITDA guidance raised to $30.0 million - $32.0 million.